Latest
By Philip Joens / Friday, September 30th, 2016 / Central Coast Health Watch, East Ventura County, Latest news / Comments Off on FDA gives big win to Amgen in biosimilars race
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Latest
By Marissa Nall / Friday, July 22nd, 2016 / Technology, Top Stories, Top Story / Comments Off on Certification gives Apeel appeal
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Latest
By Staff Report / Tuesday, July 19th, 2016 / Central Coast Health Watch, Latest news / Comments Off on FDA declines to approve Novartis biosimilar for Amgen’s Neulasta
The Food and Drug Administration has declined for now to approve a copycat version of Amgen’s blockbuster drug Neulasta. Reuters reported July 19 that the FDA sent a letter to Swiss pharmaceutical Novartis at the end of June saying it was declining to approve the drug for now. Neulasta, made by Thousand Oaks-based biotech giant Read More →
Read More →
Latest
By Dana Olsen / Friday, November 2nd, 2012 / Agribusiness, Law, Top Stories / Comments Off on Santa Maria firm sued over role in listeria outbreak
A Santa Maria company’s subcontractor was the last firm to sign off on the food-safety practices at a farm that produced listeria-laced cantaloupe that led to dozens of deaths throughout the country, several lawsuits allege. PrimusLabs is a third-party food auditor that’s hired by growers to inspect whether their facilities, equipment and practices meet industry Read More →
Read More →
Latest
By Henry Dubroff / Friday, May 20th, 2011 / Technology, Top Stories / Comments Off on Amgen drug shows blockbuster promise
Putting test results behind the talk at its recent product pipeline review, Thousand Oaks-based Amgen on May 17 released promising results for the Xgeva variant of its potential blockbuster bone drug denosumab.
Read More →